While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...
Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...
Terns Pharmaceuticals is bowing to competitive pressure and walking away from a liver disease that has long been without meaningful treatment options—until now. The biotech will shelve development of ...
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offering of $400 million ...
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases like oncology and obesity, has announced that its ...
Terns Pharmaceuticals, Inc. ( TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia December 8, 2025 4:30 PM EST ...
We recently published 10 Firms Shining Bright in a Bleeding Market. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the best-performing stocks on Monday. Terns Pharmaceuticals rallied to a new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback